Wells Fargo’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-13
| Closed | -$35 | – | 7819 |
|
|
2023
Q1 | $35 | Buy |
13
+9
| +225% | +$34 | ﹤0.01% | 7208 |
|
|
2022
Q4 | $16 | Hold |
4
| – | – | ﹤0.01% | 7332 |
|
|
2022
Q3 | $0 | Hold |
4
| – | – | ﹤0.01% | 7818 |
|
|
2022
Q2 | $0 | Buy |
4
+1
| +33% | +$9 | ﹤0.01% | 7914 |
|
|
2022
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 8228 |
|
|
2021
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 8150 |
|
|
2021
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 7809 |
|
|
2021
Q2 | $0 | Buy |
3
+1
| +50% | +$54 | ﹤0.01% | 7742 |
|
|
2021
Q1 | $0 | Hold |
2
| – | – | ﹤0.01% | 7642 |
|
|
2020
Q4 | $0 | Sell |
2
-11
| -85% | -$640 | ﹤0.01% | 7285 |
|
|
2020
Q3 | $1K | Hold |
13
| – | – | ﹤0.01% | 6259 |
|
|
2020
Q2 | $1K | Hold |
13
| – | – | ﹤0.01% | 6217 |
|
|
2020
Q1 | $1K | Buy |
+13
| New | +$1.27K | ﹤0.01% | 6110 |
|
|
2019
Q1 | – | Sell |
-14
| Closed | -$7K | – | 6592 |
|
|
2018
Q4 | $7K | Buy |
+14
| New | +$8.68K | ﹤0.01% | 6032 |
|
|
2018
Q3 | – | Sell |
-14
| Closed | -$8K | – | 6658 |
|
|
2018
Q2 | $8K | Buy |
+14
| New | +$9.13K | ﹤0.01% | 6017 |
|
Wells Fargo's HTGM Position: Q2 2023 in Review
Wells Fargo sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2023, closing a stake of 13 shares — an estimated $35 sold.
Wells Fargo first reported a position in HTGM in Q2 2018 and held it in 15 quarters. The position peaked at $8K in Q2 2018. 0 funds tracked by Wall St. Rank hold HTGM as of Q2 2023.
- Wells Fargo reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Wells Fargo sold 13 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2023, an estimated $35.
- Wells Fargo first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2018 and held it in 15 quarters.
- Wells Fargo's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $8K in Q2 2018.
- 0 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2023.
Based on Wells Fargo's 13F filing for Q2 2023, filed 15 Aug 2023.